Publicaciones en colaboración con investigadores/as de Hospital Universitario de Salamanca (9)

2023

  1. Etiopathogenic role of ERK5 signaling in sarcoma: prognostic and therapeutic implications

    Experimental and Molecular Medicine, Vol. 55, Núm. 6, pp. 1247-1257

2022

  1. ERK5 Is a Major Determinant of Chemical Sarcomagenesis: Implications in Human Pathology

    Cancers, Vol. 14, Núm. 14

2021

  1. Clinical, genetic and pharmacological data support targeting the MEK5/ERK5 module in lung cancer

    npj Precision Oncology, Vol. 5, Núm. 1

2019

  1. MEK5 promotes lung adenocarcinoma

    The European respiratory journal

2014

  1. Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer

    Oncogene, Vol. 33, Núm. 2, pp. 148-156

2013

  1. Potent antimyeloma activity of a novel ERK5/CDK inhibitor

    Clinical Cancer Research, Vol. 19, Núm. 10, pp. 2677-2687

2009

  1. Expression of Erk5 in early stage breast cancer and association with disease free survival identifies this kinase as potential therapeutic target

    PLoS ONE, Vol. 4, Núm. 5

2008

  1. The mitogen-activated protein kinase Erk5 mediates human mesangial cell activation

    Nephrology Dialysis Transplantation, Vol. 23, Núm. 11, pp. 3403-3411

2005

  1. Bortezomib is an efficient agent in plasma cell leukemias

    International Journal of Cancer, Vol. 114, Núm. 4, pp. 665-667